1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Myelofibrosis Global Clinical Trials Review, H2, 2015

Myelofibrosis Global Clinical Trials Review, H2, 2015

  • December 2015
  • -
  • GlobalData
  • -
  • 260 pages

Myelofibrosis Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Myelofibrosis Global Clinical Trials Review, H2, 2015" provides an overview of Myelofibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Myelofibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Myelofibrosis Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Figures 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Myelofibrosis to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Myelofibrosis to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Myelofibrosis Therapeutics Clinical Trials 27
Prominent Drugs 28
Clinical Trial Profile Snapshots 29
Appendix 257
Abbreviations 257
Definitions 257
Research Methodology 258
Secondary Research 258
About GlobalData 259
Contact Us 259
Disclaimer 259
Source 260

List of Figures
Myelofibrosis Therapeutics, Global, Clinical Trials by Region, 2015* 6
Myelofibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Myelofibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Myelofibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 9
Myelofibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 10
Myelofibrosis Therapeutics Clinical Trials, North America, Top Countries, 2015* 11
Myelofibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 12
Myelofibrosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 13
Proportion of Myelofibrosis to Oncology Clinical Trials, G7 Countries (%), 2015* 14
Myelofibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Myelofibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Myelofibrosis to Oncology Clinical Trials, E7 Countries (%), 2015* 17
Myelofibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Myelofibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Myelofibrosis Therapeutics, Global, Clinical Trials by Phase, 2015* 20
Myelofibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
Myelofibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Myelofibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Myelofibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Myelofibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 25
Myelofibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Myelofibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
Myelofibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 28

List of Figures
Myelofibrosis Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Myelofibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Myelofibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Myelofibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 9
Myelofibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 10
Myelofibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 11
Myelofibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 12
Myelofibrosis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 13
Proportion of Myelofibrosis to Oncology Clinical Trials, G7 Countries (%), 2015* 14
Myelofibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Myelofibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Myelofibrosis to Oncology Clinical Trials, E7 Countries (%), 2015* 17
Myelofibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Myelofibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Myelofibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20
Myelofibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21
Myelofibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Myelofibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Myelofibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Myelofibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 25
Myelofibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Myelofibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
Myelofibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 28
GlobalData Methodology 258

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Leukaemia Forecast in 18 Major Markets 2017-2027

Epiomic Epidemiology Series: Leukaemia Forecast in 18 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • January 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Leukaemia in 18 Major Markets Leukaemia refers to a group of cancers which originate in the bone marrow; they result in the overproduction ...

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic lymphocytic leukemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market  Forecast-2023

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Japan and the US - Forecast

  • March 2017
    9 pages
  • Therapy  

  • Japan  

    United States  

View report >

Cancer Statistics in the US

  • March 2017
  • Cancer  

    Pathology  

  • United States  

View report >

Sexually Transmitted Disease Statistics and Cancer Statistics in the Netherlands

  • March 2017
    213 pages
  • Sexually Transm...  

    Cancer  

    Smoking Statist...  

  • Netherlands  

    Europe  

View report >

Cancer Statistics

18 days ago

Related Market Segments :

Leukemia
Blood Disease
Therapy

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.